Transport of methotrexate, methotrexate polyglutamates, and 17β-estradiol 17-(β-D-glucuronide) by ABCG2: Effects of acquired mutations at R482 on methotrexate transport

Cancer Research

Volumn 63, Issue 14, 2003, Pages 4048-4054

  Chen, Zhe Sheng ^a   Robey, Robert W ^b   Belinsky, Martin G ^a   Shchaveleva, Irina ^a   Ren, Xiao Qin ^c   Sugimoto, Yoshikazu ^d   Ross, Douglas D ^e   Bates, Susan E ^b   Kruh, Gary D ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d CANCER CHEMOTHERAPY CENTER   (Japan)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN; CARRIER PROTEIN; ESTRADIOL 17 GLUCURONIDE; FLAVOPIRIDOL; FOLIC ACID ANTAGONIST; FOLINIC ACID; FUMITREMORGIN; METHOTREXATE; METHOTREXATE POLYGLUTAMATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; MYCOTOXIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RESISTANCE; DRUG TRANSPORT; EXPRESSION VECTOR; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MEMBRANE VESICLE; PRIORITY JOURNAL;

ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; ESTRADIOL; HUMANS; INDOLES; METHOTREXATE; MUTATION; NEOPLASM PROTEINS; POLYGLUTAMIC ACID; TRANSFECTION;

EID: 0042354831     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., and Ross, D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA, 95: 15665-15670, 1998.
2. Miyake, K., Mickley, L., Litman, T., Zhan, Z., Robey, R., Cristensen, B., Brangi, M., Greenberger, L., Dean, M., Fojo, T., and Bates, S. E. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res., 59: 8-13, 1999.
3. Allikmets, R., Schriml, L. M., Hutchinson, A., Romano-Spica, V., and Dean, M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res., 58: 5337-5339, 1998.
4. Honjo, Y., Hrycyna, C. A., Yan, Q. W., Medina-Perez, W. Y., Robey, R. W., van de Laar, A., Litman, T., Dean, M., and Bates, S. E. Acquired mutations in the MXR/ BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res., 61: 6635-6639, 2001.
5. Allen, J. D., Brinkhuis, R. F., Wijnholds, J., and Schinkel, A. H. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res., 59: 4237-4241, 1999.
6. Robey, R. W., Medina-Perez, W. Y., Nishiyama, K., Lahusen, T., Miyake, K., Litman, T., Senderowicz, A. M., Ross, D. D., and Bates, S. E. Overexpression of the ATP-binding cassette half-transporter. ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin. Cancer Res., 7: 145-152, 2001.
7. Maliepaard, M., van Gastelen, M. A., de Jong, L. A., Pluim, D., van Waardenburg, R. C., Ruevekamp-Helmers, M. C., Floot, B. G., and Schellens, J. H. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res., 59: 4559-4563, 1999.
8. Allen, J. D., Jackson, S. C., and Schinkel, A. H. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. Cancer Res., 62: 2294-2299, 2002.
9. Zeng, H., Chen, Z-S., Belinsky, M. G., Rea, P. A., and Kruh, G. D. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res., 61: 7225-7232, 2001.
10. Zeng, H., Liu, G., Rea, P. A., and Kruh, G. D. Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res., 60: 4779-4784, 2000.
11. Chen, Z-S., Lee, K., Walther, S., Blanchard Raftogianis, R., Kuwano, M., Zeng, H., and Kruh, G. D. Analysis of methotrexate and folate transport by multidrug resistance protein 4: MRP4 is a component of the methotrexate efflux system. Cancer Res., 62: 3144-3150, 2002.
12. Lee, K., Klein-Szanto, A. J., and Kruh, G. D. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J. Natl. Cancer Inst., 92: 1934-1940, 2000.
13. Kool, M., van der Linden, M., de Haas, M., Scheffer, G. L., de Vree, J. M., Smith, A. J., Jansen, G., Peters, G. J., Ponne, N., Scheper, R. J., Elferink, R. P., Baas, F., and Borst, P. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. USA, 96: 6914-6919, 1999.
14. Hooijberg, J. H., Broxterman, H. J., Kool, M., Assaraf, Y. G., Peters, G. J., Noordhuis, P., Scheper, R. J., Borst, P., Pinedo, H. M., and Jansen, G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res., 59: 2532-2535, 1999.
15. Hirohashi, T., Suzuki, H., and Sugiyama, Y. Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J. Biol. Chem., 274: 15181-15185, 1999.
16. Volk, E. L., Rohde, K., Rhee, M., McGuire, J. J., Doyle, L. A., Ross, D. D., and Schneider, E. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res., 60: 3514-3521, 2000.
17. Volk, E. L., Farley, K. M., Wu, Y., Li, F., Robey, R. W., and Schneider, E. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res., 62: 5035-5040, 2002.
18. Maliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C., Schinkel, A. H., van De Vijver, M. J., Scheper, R. J., and Schellens, J. H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res., 61: 3458-3464, 2001.
19. Kawabe, T., Chen, Z-S., Wada, M., Uchiumi, T., Ono, M., Akiyama, S., and Kuwano, M. Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett., 456: 327-331, 1999.
20. Zeng, H., Bain, L. J., Belinsky, M. G., and Kruh, G. D. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res., 59: 5964-5967. 1999.
21. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.
22. Cornwell, M. M., Gottesman, M. M., and Pastan, I. H. Increased vinblastine binding to membrane vesicles from multidrug- resistant KB cells. J. Biol. Chem., 261: 7921-7928, 1986.
23. Leier, I., Jedlitschky, G., Buchholz, U., Cole, S. P., Deeley, R. G., and Keppler, D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. Biol. Chem., 269: 27807-27810, 1994.
24. Rabindran, S. K., Ross, D. D., Doyle, L. A., Yang, W., and Greenberger, L. M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res., 60: 47-50, 2000.
25. Masuda, M., I'izuka, Y., Yamazaki, M., Nishigaki, R., Kato, Y., Ni'inuma, K., Suzuki, H., and Sugiyama, Y. Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res., 57: 3506-3510. 1997.
26. Niinuma, K., Takenaka, O., Horie, T., Kobayashi, K., Kato, Y., Suzuki, H., and Sugiyama, Y. Kinetic analysis of the primary active transport of conjugated metabolites across the bile canalicular membrane: comparative study of S-(2, 4-dinitrophenyl)-glutathione and 6-hydroxy-5, 7-dimethyl-2-methylamino-4-(3-pyridylmethyl)benzothiazole glucuronide. J. Pharmacol. Exp. Ther., 282: 866-872, 1997.
27. Nishino, A., Kato, Y., Igarashi, T., and Sugiyama, Y. Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisaltan. Drug Metab. Dispos., 28: 1146-1148, 2000.
28. Chen, Z-S., Lee, K., and Kruh, G. D. Transport of cyclic nucleotides and estradiol 17-β-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J. Biol. Chem., 276: 33747-33754, 2001.
29. Loe, D. W., Almquist, K. C., Cole, S. P., and Deeley, R. G. ATP-dependent 17 β-estradiol 17-β-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J. Biol. Chem., 271: 9683-9689, 1996.
30. Jedlitschky, G., Leier, I., Buchholz, U., Barnouin, K., Kurz, G., and Keppler, D. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res., 56: 988-994, 1996.
31. Cui, Y., Konig, J., Buchholz, J. K., Spring, H., Leier, I., and Keppler, D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein. MRP2, permanently expressed in human and canine cells. Mol. Pharmacol., 55: 929-937, 1999.
32. Whitehead, V. M. Synthesis of methotrexate polyglutamates in L1210 murine leukemia cells. Cancer Res., 37: 408-412, 1977.
33. Rosenblatt, D. S., Whitehead, V. M., Vera, N., Pottier, A., Dupont, M., and Vuchich, M. J. Prolonged inhibition of DNA synthesis associated with the accumulation of methotrexate polyglutamates by cultured human cells. Mol. Pharmacol., 14: 1143-1147, 1978.
34. Gewirtz, D. A., White, J. C., Randolph, J. K., and Goldman, I. D. Formation of methotrexate polyglutamates in rat hepatocytes. Cancer Res., 39: 2914-2918, 1979.
35. McGuire, J. J., Hsieh, P., Coward, J. K., and Bertino, J. R. Enzymatic synthesis of folylpolyglutamates. Characterization of the reaction and its products. J. Biol. Chem., 255: 5776-5788, 1980.
36. Garrow, T. A., Admon, A., and Shane, B. Expression cloning of a human cDNA encoding folylpoly(γ-glutamate) synthetase and determination of its primary structure. Proc. Natl. Acad. Sci. USA, 89: 9151-9155, 1992.
37. Saxena, M., and Henderson, G. B. Identification of efflux systems for large anions and anionic conjugates as the mediators of methotrexate efflux in L1210 Cells. Biochem. Pharmacol., 51: 974-982, 1996.
38. Schlemmer, S. R., and Sirotnak, F. M. Energy-dependent efflux of methotrexate in L1210 leukemia cells. Evidence for the role of an ATPase obtained with inside-out plasma membrane vesicles. J. Biol. Chem., 267: 14746-14752, 1992.
39. Jolivet, J., Schilsky, R. L., Bailey, B. D., Drake, J. C., and Chabner, B. A. Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells. J. Clin. Investig., 70: 351-360, 1982.
40. Galivan, J., and Balinska, M. Studies of formation and efflux of methotrexate polyglutamates with cultured hepatic cells. Adv. Exp. Med. Biol., 163: 235-246. 1983.
41. Galivan, J., and Nimec, Z. Effects of folinic acid on hepatoma cells containing methotrexate polyglutamates. Cancer Res., 43: 551-555, 1983.
42. Nakatomi, K., Yoshikawa, M., Oka, M., Ikegami, Y., Hayasaka, S., Sano, K., Shiozawa, K., Kawabata, S., Soda, H., Ishikawa, T., Tanabe, S., and Kohno, S. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem. Biophys. Res. Commun., 288: 827-832, 2001.
43. Ozvegy, C., Litman, T., Szakacs, G., Nagy, Z., Bates, S., Varadi, A., and Sarkadi, B. Functional characterization of the human multidrug transporter. ABCG2, expressed in insect cells. Biochem. Biophys. Res. Commun., 285: 111-117, 2001.
44. Kruh, G. D., Zeng, H., Rea, P. A., Liu, G., Chen, Z-S., Lee, K., and Belinsky, M. G. MRP subfamily transporters and resistance to anticancer agents. J. Bioenerg. Biomembr., 33: 493-501, 2001.
45. Kruijtzer, C. M., Beijnen, J. H., Rosing, H., ten Bokkel Huinink, W. W., Schot, M., Jewell, R. C., Paul, E. M., and Schellens, J. H. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J. Clin. Oncol., 20: 2943-2950, 2002.
46. Jonker, J. W., Smit, J. W., Brinkhuis, R. F., Maliepaard, M., Beijnen, J, H., Schellens, J. H., and Schinkel, A. H. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst., 92: 1651-1656, 2000.
47. Imai, Y., Tsukahara, S., Ishikawa, E., Tsuruo, T., and Sugimoto, Y. Estrone and 17β-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Jpn. J. Cancer Res., 93: 231-235, 2002.
48. Scheffer, G. L., Maliepaard, M., Pijnenborg, A. C., van Gastelen, M. A., de Jong, M. C., Schroeijers, A. B., van der Kolk, D. M., Allen, J. D., Ross, D. D., van der Valk, P., Dalton, W. S., Schellens, J. H., and Scheper, R. J. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res., 60: 2589-2593, 2000.
49. Morikawa, A., Goto, Y., Suzuki, H., Hirohashi, T., and Sugiyama, Y. Biliary excretion of 17β-estradiol 17β-D-glucuronide is predominantly mediated by cMOAT/ MRP2. Pharm. Res., 17: 546-552, 2000.
50. Marquardt, D. W. An algorithm for nonlinear estimation of nonlinear parameters. J. Soc. Ind. Appl. Math, 11: 431-441, 1963.